Synuclein quantitation in plasma using LC-MRM

# 1 Absolute quantification of synuclein proteoforms in plasma in

- <sup>2</sup> patients with Synucleinopathies by LC-MRM mass spectrometry
- 3
- 4 Pons Marie-Laure<sup>1, 2</sup>, Vignon Margaux<sup>1</sup>, Vialaret Jérôme<sup>1</sup>, Mondesert Etienne<sup>1</sup>,
- 5 Moreau Stéphane<sup>2</sup>, Lehmann Sylvain<sup>1</sup> and Hirtz Christophe<sup>1</sup>
- <sup>1</sup> IRMB, Univ Montpellier, INM, INSERM, CHU Montpellier, (LBPC-PPC), Montpellier,
- 7 France
- <sup>2</sup> Shimadzu Corporation, Albert-Hahn-Straße, Duisburg Germany
- 9 marielaurepons43@gmail.com (+33 4 67 33 71 73), margaux.vignon@umontpellier.fr

10 (+33 4 67 33 04 20), j-vialaret@chu-montpellier.fr (+33 4 67 33 71 73), e-

- 11 mondesert@chu-montpellier.fr (+33 4 67 33 83 46), sm@shimadzu.eu (+49-203-
- 12 76870), sylvain.lehmann@umontpellier.fr (+33 4 67 33 71 23) and
- 13 christophe.hirtz@umontpellier.fr (+33 4 67 33 04 20).

14 Corresponding author : Pons Marie-Laure, marielaurepons43@gmail.com (+33 4 67

15 33 71 73).

16

Synuclein quantitation in plasma using LC-MRM

### 17 Abstract

Background : Synucleinopathies include Parkinson's disease (PD), Lewy body dementia (LBD) and Multiple system atrophy (MSA). Most studies of synucleinopathies rely on immunoassays to quantify total or oligomeric alpha synuclein. Immunoassay results are variable due to the inconstant nature of antibodies and different studies found higher, lower or equal levels of alpha synuclein between PD and control patients in biological matrixes. Mass spectrometry, has less inherent variability.

Methods : Therefore, we developed the first reliable and validated mass spectrometry method to quantify synuclein proteoforms in human plasma using liquid chromatography coupled to mass spectrometry with multiple reaction monitoring mode (LC-MRM) mass spectrometry,

29 Results : The study followed European and International guidelines (Food and Drug 30 administration and European Medicines Agency) and paves the way for precise 31 multiplex quantitation of synucleinopathies. Using a cohort of 143 patients with 32 synucleinopathies and controls we found a peptide ratio and combination between  $\alpha$ -33 syn EQVTNVGGAVVTGVTAVAQK and  $\alpha/\beta$ -syn EGVLYVGSK peptides that 34 discriminated PD patients from the other diseases (LBD, MSA and controls). The 35 sensitivity and specificity (Area Under ROC Curve) of the method to distinguish 36 between patients with PD and control patients was 0.84 and 0.76 (0.787), for PD vs 37 LBD the values were 0.7 and 0.68 (0.743), and 0.85 and 0.85 (0.831) for PD vs MSA. Conclusions : The developed and validated LC-MRM method presented here could 38 39 be used in clinical to discriminate PD from other synucleinopathies and control 40 patient.

41

Synuclein quantitation in plasma using LC-MRM

- 42 Keywords: Parkinson's disease, alpha synuclein, immunoassay, mass spectrometry,
- 43 proteoforms, ratio and combination of peptides.

Synuclein quantitation in plasma using LC-MRM

# 44 Introduction

Synucleinopathies are a group of pathologies that share cognitive, motor, non-motor symptoms and molecular inclusions composed of alpha synuclein. The three most well-known and common such pathologies are Lewy bodies Dementia (LBD), Parkinson's disease (PD) and multi system atrophy (MSA)<sup>1</sup>. There are three kinds of synuclein: alpha, beta and gamma synuclein, that are all present in pre-synaptic terminals in dopaminergic neurons.

51 Alpha synuclein inclusions, called Lewy bodies and Lewy neurites, are made of 52 aggregated, fibrillar, phosphorylated, ubiquitinated and truncated alpha synuclein 53 species. These inclusions are retrieved in the cytoplasm of the dopaminergic neurons for PD and LBD pathologies and found in oligodendrocytes for MSA patients<sup>1</sup>. Lewy 54 bodies are responsible for the neurodegeneration observed in synucleinopathies<sup>2</sup>. 55 56 Therefore, this protein and its proteoforms have been proposed as biomarkers for these pathologies<sup>3</sup>. Synuclein proteoforms include serine 129 phosphorylated, some 57 58 C-terminal truncations and ubiquitination sites or alternatively spliced alpha synuclein isoforms with 126, 112, 98 and 41 amino acids<sup>4</sup>. Indeed, the alpha synuclein spliced 59 60 variants have been found in different mRNA level in synucleinopathies. α-syn 61 alternative proteins also arise from a reading frameshift (+2 instead of +1) resulting in different and shorter protein than the full length alpha synuclein (140 aa). This type of 62 63 species could potentially play a role in the pathogenesis of neurodegenerative disease<sup>5</sup>. 64

65 Beta synuclein is not detected in aggregates or fibrils in brains with synucleinopathies 66 and has a lower propensity to aggregate than alpha synuclein due to the absence of

Synuclein quantitation in plasma using LC-MRM

the 73-83 AA part of the non-amyloid component domain<sup>6</sup>. Gamma synuclein has
 been detected in fibril form in PD brains<sup>7</sup>.

69 For several years, synucleins have been studied, and especially alpha synuclein, due 70 to their potential biomarker value in neurodegenerative disorders. So far, detection 71 and quantification of synucleins (total, oligomeric and phosphorylated at S129) in 72 human biological fluids has mainly been achieved via antibody-based assays such as 73 ELISA <sup>3,8</sup>. This approach may undergo some bias due to nonspecific detection and 74 antibody affinity variability. Indeed, immunoassay kits gave highly variable results in 75 absolute concentration and with alpha synuclein level retrieved in biological fluid (cerebrospinal fluid<sup>9</sup>, plasma and saliva). 76

To counteract antibody-based method (ELISA) issues, clinical mass spectrometry (MS) approaches have been successfully developed to improve protein and proteoform quantification<sup>10</sup>. Indeed, MS is a powerful tool thanks to accurate, specific and multiplex quantitation. These performances are due to the analysis of mass on charge (m/z) of ions from proteotypic peptides after sample ionisation<sup>11</sup>. In multiple reaction monitoring (MRM), at least three transitions, corresponding to the fragmentation of the precursor ion into products ions, are monitored<sup>12</sup>.

In conclusion, the concentration differences of alpha synuclein observed in synucleinopathies in CSF, the lack of study using MS quantification (3), the risk of interference by blood contamination during lumbar puncture <sup>13</sup> and the high expression of alpha synuclein in erythrocyte<sup>14</sup>, supports the notion that total alpha synuclein in CSF is not a useful diagnostic biomarker for synucleinopathies<sup>7</sup>.

Synuclein quantitation in plasma using LC-MRM

89	Here we present a validated and targeted mass spectrometry method to quantify
90	synucleins proteoforms in plasma patient samples with synucleinopathies. This
91	quantification method was compared with sensitive immunoassay measurement.
92	Materials and methods

93 Reagents and internal standards

Recombinant human full-length alpha synuclein ( $\alpha$ -syn) and the recombinant full-94 length  $\alpha$ -syn with uniform <sup>15</sup>N-label came from LGC (Teddington, UK). The 95 recombinant beta and gamma synuclein ( $\beta$ -syn and y-syn) with uniform <sup>15</sup>N-label 96 97 were purchased from Promise Advanced Proteomics (Grenoble, France). The beta and gamma recombinant light form came from Anaspec (Fremont, California, USA) 98 and Interchim (Montlucon, France) respectively. Light protein standard concentration 99 100 was determined for α-syn by electrochemiluminescence with the U-PLEX Human α-101 Synuclein immunoassay kit purchased from MesoScale Discovery system (Rockville, Maryland, USA). MS grade Trypsin/LysC, rLysC, Glu-C and Lys-N were purchased 102 103 from Promega GmbH (Walldorf, Germany). Ammonium bicarbonate, perchloric acid, 104 trifluoroacetic acid and human serum albumin (HSA) were ordered from Sigma 105 Aldrich (Saint Quentin Fallavier, France). RP-W Cartridge tips were purchased from Agilent technologies (Santa Clara, California, USA). MS-grade liguid chromatography 106 107 solvents: acetonitrile, water and formic acid were purchased from Biosolve (Dieuze, 108 France). AQUA (absolute quantitation) peptides for  $\alpha$ -syn-126/98;  $\alpha$ -syn-112/98 and 109 a-syn-41 came from Thermofisher scientific (Lincoln, Massachusetts, USA) with a purity of 99%. Specific peptides of the alternative  $\alpha$ -syn and its mutated form were 110 111 also purchased from Thermofisher scientific (Lincoln, Massachusetts, USA) with a

Synuclein quantitation in plasma using LC-MRM

112 purity of 95%. Goat serum (capra hircus) was ordered from Clinisciences (Nanterre,

113 France).

114 Stock Solutions, Calibration Standards, and Quality Control (QC) samples

115 Protein and peptide standards were dissolved in 50 mM ammonium bicarbonate to a

116 final concentration of 1µg/µl. Aliquots of 10 µl were dispensed into low protein-

<sup>117</sup> binding Eppendorf tubes and stored at -20 °C or -80 °C, according to the suppliers'

instructions.

119 Method development and validation were performed on plasma QC samples at three

120 concentration levels: low (45  $\pm$  6.2) ng/ml, medium (87  $\pm$  16.9 ng/ml) and high (230  $\pm$ 

121 30.4 ng/ml), quantified by electrochemiluminescence (MesoScale Discovery).

Patient samples from the laboratory biobank were thawed at 4°C for one hour. They were put in a 50 ml falcon and mixed for several minutes. They were then realiquoted (50µl per tube) and stored at -80°C until analysis.

125 MS Calibration

126 9 points of calibration were prepared by diluting recombinant light  $\alpha$ -syn,  $\beta$ -syn and  $\gamma$ -127 syn standards into goat (capra hircus) serum. Calibration ranges (detailed in Table S2 in supplemental data) were as follows: [0-5571] ng/mL for  $\alpha$ -syn, [0-410] ng/mL 128 129 for  $\beta$ -syn and [0-1401] ng/mL for y-syn. The calibration range for labelled peptides (AQUA) including N-terminal peptide, peptides from  $\alpha$ -syn isoforms, and peptides 130 131 from  $\alpha$ -syn alternative protein, were performed separately on 8 points and the 132 concentration of each peptide is described in Table S3 in supplemental data. Peptide concentrations were calculated based on the calibration curve (weighting  $1/x^2$ ) using 133 134 Skyline software.

Synuclein quantitation in plasma using LC-MRM

### 135 Sample Preparation

95 µl of plasma samples were thawed on ice for 1 hour. Then 855 µl of deionised 136 water was added. Samples were then supplemented with 5.7 µl of 10 ng/µl internal 137 standard of recombinant labelled U-<sup>15</sup>N alpha, beta and gamma synuclein in 50 mM 138 139 ammonium bicarbonate. Samples were mixed and the proteins were precipitated by 140 incubation on ice for 15 minutes with 142.5 µl of 70% perchloric acid. After incubation, samples were spun at 16,000 g for 15 min at 4°C, and the supernatants 141 142 were collected into new LoBind tubes with the addition of 95 µl of 1% trifluoroacetic acid. After a volume reduction by vacuum-drying at room temperature (Speedvac, 143 Labconco), the supernatants were cleaned up on RP-W cartridges using the 144 AssayMap Bravo (Agilent technologies) into a LoBind 96 deep well plate. The 145 146 cartridges were washed out with water at an aspiration speed of 10 µl/min and then samples were loaded on the cartridges at 5 µl/min. Proteins were washed out on 147 bravo tips with 10% acetonitrile and 0.1% formic acid at 10 µl/min and eluted with 148 149 45% acetonitrile and 0.1% formic acid at 5 µl/min. Samples were evaporated dry at 150 room temperature under vacuum for 1h30 using a Speedvac. The samples were 151 reconstituted with 20µl of 50mM ammonium bicarbonate. Finally, 7 µl of 1µg/µl 152 trypsin/lysC were added. Plasma samples were incubated for 4 hours at 37°C with gentle agitation (450 rpm). After incubation, 0.5 µL of formic acid was added to the 153 154 samples.

Liquid chromatography-mass spectrometry multiple reaction monitoringanalysis

Samples were analysed using a Shimadzu liquid chromatography system (Mikros)
 and a triple quadrupole - Shimadzu 8060 mass spectrometer (Duisburg, Germany) in

Synuclein quantitation in plasma using LC-MRM

159 positive ionization mode. 15µl of sample were injected on a ZORBAX SB-Aq (1 x 150 160 mm, 3.5 µm) column from Agilent technologies, at 35°C. The mobile phase A was 161 composed of water with 0.1% of formic acid and the mobile phase B was composed 162 of acetonitrile with 0.1% of formic acid. The solvent gradient consisted of a slow 163 increase of the organic solvent (phase B) from 0% to 30% over 30 min. Total run time 164 for the analysis was 40 min at a flow rate of 50µl/min. The minimum dwell time used 165 was 20 ms per peptide. The ion source parameters were 3 L/min for the nebulizing gas flow, 10 L/min for the heating gas flow, 300°C for the interface temperature, 166 167 250°C for the desolvation line temperature, 400°C for the heat block temperature and 168 10L/min for the drying gas flow. Between three and six transitions were acquired for 169 each peptide in biological samples. Peptide position, selection and transitions of the 170 synucleins are described in Table S1 in supplemental data. The concentration of the 171  $\alpha$ -syn and  $\beta$ -syn peptides was determined by comparing unlabelled and labelled 172 peptides with LC-MRM analysis.

173 Analytical method validation

174 The intra and inter–assay repeatability was determined by analysing three QC 175 plasma at three different levels of  $\alpha$ -syn (high, medium and low) per day over 4 days.

Sample stability was determined by analysis three aliquots of goat serum thawed on ice or at room temperature for 6h. In addition, three QC plasma were stored until 48h into the liquid chromatography autosampler at 4°C. Dilution and parallelism stability was determined by dilution of goat serum with ammonium bicarbonate up to fourfold.

Matrix effect was determined by comparing the MS signal between spiked normal goat serum (n=3) with heavy recombinant standards after digestion and spiked solvent (n=3) after digestion at the same concentration.

Synuclein quantitation in plasma using LC-MRM

The lower limit of quantification was defined as the lowest concentration with a CV superior to 20% and a signal to noise ratio > 5.

185 Immunoassay

Plasma samples were analysed by immunochemiluminescence assay with a MesoScale Discovery. Plasma samples were diluted 200-fold for the determination of the total alpha synuclein concentration. All measurements were performed according to the manufacturer's instructions. Antibodies were directed against  $\alpha$ -syn C-terminal part (110-125) for capture (rabbit monoclonal antibody) and the mouse monoclonal detection antibody was against amino acids 15-125.

#### 192 Patients and Biofluid Collection

193 All the participants gave their written consent to be enrolled in the study which was 194 approved by the Montpellier University Hospital's regional Ethics Committee. General 195 characteristics of the 143 patients are presented in Table 1. Mean age of the population was 71 (±8.2) years, and 65 % were men. The cohort was divided in three 196 197 disease groups: PD (n=82), LBD (n=32) and MSA (n=8) and a group of control 198 patients (n=21). Control patients suffered from non-neurodegenerative diseases such 199 as neurologic disorders including neuropathic affections (23.8 %), vascular affections 200 (28.6 %), immunologic affections (28.6%) and hydrocephalus (19.0 %). Exclusion 201 criteria for the control group was an abnormal Alzheimer biomarker profile (i.e. low 202 Aβ 42/40 ratio and increased tau/ptau protein concentration). Regarding patients with 203 Parkinson's diseases, diagnosis was determined on average 11 (± 7.4) years before 204 analysis. At diagnosis 41.9% had cognitive impairment and 69.7% presented non 205 motor signs. Mean Hoehn and Yahr score (corresponding to the Unified Parkinson's 206 Disease Rating Scale V) was 2.4 (± 0.7). Unified Parkinson's Disease Rating Scale II

Synuclein quantitation in plasma using LC-MRM

and III scores were respectively, 19.7 ( $\pm$  11.2) and 36 ( $\pm$  18.9), corresponding to a light or moderate motor impairment. Plasma collected by venous puncture were stored at the Montpellier Neurobank (#DC-2008-417 of the certified NFS 96-900 CHU resource center BB-0033-00031). Authorization to handle personal data was granted by the French Data Protection Authority (CNIL).

212 Data analysis

The extraction of LC-MS chromatograms of synucleins peptides for quantification was realized using Skyline Software (20.1.0 version) and LabSolutions Insight Browser. Liquid chromatography-mass spectrometry with multiple reaction monitoring mode analyses were launched with LabSolutions software (5.99 version).

217 Statistical analysis was performed with MedCalc (19.0.3. version) and the normality 218 of the data set were checked by Shapiro-Wilk test. Comparisons between the two 219 groups were performed by Mann Whitney Wilcoxon method and clinical performance 220 ROC were assessed by curve. А statistical model: (α-syn [EQVTNVGGAVVTGVTAVAQK]\*-0.011268 +  $\alpha/\beta$ -syn [EGVLYVGSK] \* 0.0096545) 221 222 that defines the results was investigated by logistic regression with 'backward' and 223 'enter' methods. To select the model within the two methods, we set the following 224 parameters: p-value <0.05, a minimal number of variables (2) and if both logistic 225 regression methods gave the same coefficient result.

226 **Results** 

227 Method development and optimization

To quantify alpha synuclein, we selected all the proteotypic peptides, except the Cterminal part that covers about 70% of the protein sequence. The C-terminal peptide

Synuclein quantitation in plasma using LC-MRM

230 is a long peptide (38 aa), mainly composed of acidic residues and many post-231 translational modifications (phosphorylation, nitration and truncations) that impact the 232 MS signal. In plasma, this C-terminal peptide was constantly under the limits of 233 quantification. All the peptides and transitions were selected based on the sensitivity and specificity observed in the biological sample compared to the spiked internal 234 235 labelled standards. All the MS parameters (tension applied in all quadrupoles) were 236 optimized for synuclein and haemoglobin peptides and are described in Table S1 in supplemental data. We applied the same methodology for  $\beta$ -syn and  $\gamma$ -syn. 237 238 The entire workflow for the liquid chromatography-mass spectrometry with multiple 239 reaction monitoring mode analysis of the alpha synuclein peptides in plasma is

illustrated in Figure 1.

241 Analytical method validation

Both  $\beta$ -syn and  $\gamma$ -syn were constantly below the limit of quantification in the patient samples and plasma QC samples at all three levels of  $\alpha$ -syn concentration (high, medium and low). The alternative splicing isoforms and alternative  $\alpha$ -syn peptides were also under the limit of quantification.  $\alpha$ -syn and  $\alpha/\beta$ -syn common peptides were detected and quantified in all QC and patient samples.

Intra and Inter-assay repeatability was less than 20 % for alpha synuclein peptides in low concentration QCs, except for TVEGAGSIAAATGFVK peptides that were at 22% in low QCs. In medium level QCs the coefficient of variation (CV) was  $\leq 16\%$  and  $\leq 14\%$  in high QCs for  $\alpha$ -syn peptides, except for EGVVHGVATVAEK and (ac)MDVFMK peptides (CV >30%). Therefore, these peptides were excluded from further clinical validation.

Synuclein quantitation in plasma using LC-MRM

The limit of quantification range was between 6.45 and 19.35 ng/ml for  $\alpha$ -syn peptides and  $\alpha/\beta$ -syn common peptides. The linearity ranged from 0 to 5571 ng/ml for  $\alpha$ -syn peptides. The linearity range was from 0 to 5981 ng/ml for  $\alpha/\beta$ -syn common peptides.

<sup>257</sup> The synuclein peptides was stable when stored at 4°C until 48h, stable when thaw on

ice until 6h and 4h at room temperature

The analytical validation parameters of the synuclein peptides are detailed in supplemental data in Table S4 and S5.

261 Clinical validation

In total 143 plasma samples were quantified, divided in 4 groups: the PD group (n=82), the MSA group (n=8), the LBD group (n=32) and the control group (n=21). All samples were acquired by MS and immunoassay. Details of the studied population are summarized in the Table 1.

To determine the clinical performance, we evaluated the area under ROC curve (AUC), the sensitivity and specificity, and the p-value to distinguish between pathological groups. The clinical performance results for alpha synuclein peptides in plasma patient samples are presented in details in Table 2.

All peptides were able to distinguish PD patients from control patients, except for the  $\alpha$ -syn TVEGAGSIAAATGFVK peptide. The best performance peptide was  $\alpha/\beta$ -syn EGVLYVGSK followed by  $\alpha$ -syn QGVAEAAGK. Indeed, these peptides also separated the LBD group from PD and controls groups. The  $\alpha/\beta$ -syn EGVLYVGSK peptide discriminated MSA patients from controls and gave the best clinical performance to distinguish PD and control patients. Respectively, the sensitivity and

Synuclein quantitation in plasma using LC-MRM

specificity were 0.84 and 0.76 for PD vs control. The clinical performance of the  $\alpha/\beta$ syn EGVLYVGSK peptide (PD vs control) are illustrated via ROC curve in supplemental data in Figure 1.

No peptides discriminated the PD group from the MSA group. To counteract this issue, we applied a model combination of peptides. Thanks to logistic regression, a peptide combination was found comprising these two following peptides:  $\alpha$ -syn EQVTNVGGAVVTGVTAVAQK and  $\alpha/\beta$ -syn EGVLYVGSK, with the following coefficient -0.011268 and 0.0096545, respectively. The data comparison graph between groups for the peptide combination are described in Figure 2.

The obtained combination of these two peptides gave good discrimination of the PD group from the MSA patients (P=0.0021). Due to their opposite coefficient signs, we also investigated a ratio of the two alpha syn peptides to distinguish the four groups.

The best clinical performance for distinguishing PD from DLB or MSA was obtained with the peptide combination. Indeed, a sensitivity and specificity of 0.7 ,0.68 and 0.84, 0.85 respectively were obtained. The ROC curve describing the clinical performance of the peptide combination in PD vs LBD is demonstrated in Figure 3A, and similarly, Figure 3B describes the clinical performance of the peptide combination in PD vs MSA

294 Immunoassay quantification

The same plasma cohort has also been quantified by sensitive immunochemiluminescence assay. The data comparison graph between disease is presented in supplemental data Figure 2. No significant differences in  $\alpha$ -syn level quantified by immunochemiluminescence assay were observed between diseases. A slightly lower level in the control group compared to the PD group was observed.

Synuclein quantitation in plasma using LC-MRM

#### 300 Correlation

All the alpha and beta synuclein peptides were correlated together (r>0.7). No correlation was found between patient characteristics (age, sex, sampling date) and synuclein peptides (including combinations and ratios) with -0.5<r<0.5. Also, no correlation between MS quantitation and immunochemiluminescence quantitation was found (-0.3<r<0.3). No correlation between motor (UPDRS II, III or V) or nonmotor symptoms and cognitive symptoms were observed (-0.3<r<0.3).

## 307 Discussion

308 In this study MS clinical validation allowed us to observe a significant increase of five 309 a-syn peptides, in PD plasma patients compared to control. The same patients were 310 quantified by sensitive immunoassay for total alpha synuclein and no significant 311 difference was observed between disease groups. The most important difference 312 between these two methods is the variability introduced by the use of antibodies in 313 immunoassays. In this case, the antibodies used targeted the C-terminal part of the 314 proteins, which is problematic as this undergoes numerous post-translational 315 modifications and truncations. These variations impact the total concentration of this protein as perceived by immunoassay<sup>15</sup>. Indeed, the immunoassay readout did not 316 correlate with any of the alpha synuclein peptides we observed in our MS pipeline. 317 318 However, all the synuclein peptides correlated amongst themselves indicating that 319 they are a robust measure of alpha synuclein levels.

One of our main aims of our study was to discriminate different synucleinopathies and controls. Regarding this particular point, we investigated a peptide combination and a ratio of alpha syn peptides and succeeded in differentiating PD from other groups with good sensitivity and specificity (more than 80% for sensitivity and

Synuclein quantitation in plasma using LC-MRM

between 70% and more than 80% for specificity depending on pathologies). This 324 325 strategy was reminiscent of studies of AD that found that the ratio between amyloid 326 peptides (Aβ40/42) can detect the disease. The ratio of Aβ40/42 in AD allows a better discrimination and enhanced clinical performance of AD patients even at 327 prodromal stage compared to the quantification of the two separated peptides<sup>16</sup>. 328 329 There may be some biological parallels here as alpha synuclein has already shown 330 some similarity in aggregation mechanism with the amyloid beta peptides. Indeed, the peptides comprised in our peptide combination for alpha synuclein come from 331 332 differentially affected parts of the protein. In the first place the  $\alpha/\beta$ -syn EGVLYVGSK 333 peptide (position 35-43 on sequence), is part of the N-terminal region. McGlinchey et al. 2021<sup>17</sup> have described those residues 36-40 as being important for full-length 334 structure and for the formation fibrils. These results mean that the N-terminal part can 335 336 modulate the mechanism of amyloid formation and the molecular interactions of fibril assembly<sup>17</sup>. On the other hand the  $\alpha$ -syn EQVTNVGGAVVTGVTAVAQK peptide 337 338 (position 61-80 on sequence), is part of the non-amyloid component domain that constitutes the fibril core of the protein and is responsible of the aggregation 339 process<sup>17,18</sup>. 340

341 While tantalizing, the utility of peptide combination/ratio will now need to be confirmed in a larger study. For example the specificity with which we can distinguish PD from 342 343 MSA patients will need confirmation in a larger cohort, as MSA is rare with a prevalence estimated between 0.6 and 1.6 case per 100 000 habitants per year<sup>19</sup>. 344 345 For PD, misdiagnosis is estimated at approximatively 25 % and with well-established biomarkers, the disease could be detected 10 years earlier than it currently is<sup>20,21</sup>. We 346 also note that none of our lead peptides correlated to PD severity (Unified 347 348 Parkinson's Disease Rating Scale UPDRS II, III and V). This could be due to the fact

Synuclein quantitation in plasma using LC-MRM

that most of the PD patients in our cohort were similarly affected with only light ormoderate evolution.

## 351 Conclusion

Here we developed for the first time a validated method for the quantitation of synuclein peptides in plasma patients with synucleinopathies by a targeted and multiplex liquid chromatography coupled to mass spectrometry method.

355 We established a combination and ratio of alpha synuclein peptides, that distinguishing MSA from PD patients with good sensitivity and specificity (more than 356 357 80% for each). The AUC or sensitivity and specificity obtained for the ratio and 358 combination were satisfying and similar to the clinical performance obtained for 359 Aβ40/42 ratio that is use in AD clinical routine diagnostic. We can also distinguish PD 360 patients from control and LBD pathology which is a strong finding and might 361 revolutionize the synucleinopathies domain as the CSF biomarkers did for AD several 362 years ago. The results reported here support the fact that this method will be used in 363 clinical diagnosis but they may also be important for treatments targeting abnormal 364 conformations of alpha synuclein.

365

Synuclein quantitation in plasma using LC-MRM

# 366 References

- 1. Cova I, Priori A. Diagnostic biomarkers for Parkinson's disease at a glance: where are
- 368 we? J Neural Transm (Vienna Austria 1996) 2018;125:1417–32.
- 2. Mehra S, Sahay S, Maji SK. α-Synuclein misfolding and aggregation: Implications in
- 370 Parkinson's disease pathogenesis. Biochim Biophys Acta BBA Proteins Proteomics
- 371 2019;1867:890–908.
- 372 3. Schmid AW, Fauvet B, Moniatte M, Lashuel HA. Alpha-synuclein Post-translational
- 373 Modifications as Potential Biomarkers for Parkinson Disease and Other
- 374 Synucleinopathies. Mol Cell Proteomics MCP 2013;12:3543–58.
- 4. Vinnakota RL, Yedlapudi D, Manda KM, Bhamidipati K, Bommakanti KT, RangaLakshmi
- GS, Kalivendi SV. Identification of an Alternatively Spliced α-Synuclein Isoform That
- 377 Generates a 41-Amino Acid N-Terminal Truncated Peptide, 41-syn: Role in Dopamine
- Homeostasis. ACS Chem Neurosci 2018; 9:2948-58.
- 5. Mohaupt P, Roucou X, Delaby C, Vialaret J, Lehmann S, Hirtz C. The alternative
- proteome in neurobiology. Front Cell Neurosci 2022;16:1019680.
- 381 6. Kim TE, Newman AJ, Imberdis T, Brontesi L, Tripathi A, Ramalingam N, et al. Excess
- 382 membrane binding of monomeric alpha-, beta- and gamma-synuclein is invariably
- associated with inclusion formation and toxicity. Hum Mol Genet 2021;30:2332–46.
- 384 7. Oeckl P, Metzger F, Nagl M, Von Arnim CA, Halbgebauer S, Steinacker P, et al. Alpha-,
- 385 Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction
- 386 Monitoring Reveals Increased Concentrations in Alzheimer's and Creutzfeldt-Jakob
- 387 Disease but No Alteration in Synucleinopathies. Mol Cell Proteomics MCP
- 388 2016;15:3126–38.
- Tsao HH, Huang CG, Wu YR. Detection and assessment of alpha-synuclein in Parkinson
   disease. Neurochem Int 2022;158:105358.
- 391 9. Mollenhauer B, Bowman FD, Drake D, Duong J, Blennow K, El-Agnaf O, et al. Antibody-
- 392 based methods for the measurement of  $\alpha$ -synuclein concentration in human

Synuclein quantitation in plasma using LC-MRM

- 393 cerebrospinal fluid method comparison and round robin study. J Neurochem 2019;149:
- 394 126–38.
- 10. Delaby C, Vialaret J, Hirtz C, Lefebvre T, Herkert M, Puy H, et al. Analytical comparison
- 396 of ELISA and mass spectrometry for quantification of serum hepcidin in critically ill
- 397 patients. Bioanalysis 2021;13:1029–35.
- 398 11. Downard KM. 1912: a titanic year for mass spectrometry. J Mass Spectrom
- 399 2012;47:1034-9.
- 400 12. Vialaret J, Broutin S, Pugnier C, Santelé Sophie, Jaffuel A, Barnes A, et al. What sample
- 401 preparation should be chosen for targeted MS monoclonal antibody quantification in
- 402 human serum? Bioanalysis 2018;10:723–35.
- 403 13. Barkovits K, Kruse N, Linden A, Tönges L, Pfeiffer K, Mollenhauer B, Marcus K. Blood
- 404 Contamination in CSF and Its Impact on Quantitative Analysis of Alpha-Synuclein. Cells
  405 2020;9:370.
- 406 14. Tönges L, Buhmann C, Klebe S, Klucken J, Kwon EH, Müller T et al. Blood-based
- 407 biomarker in Parkinson's disease: potential for future applications in clinical research and
- 408 practice. J Neural Transm 2022;129:1201–17.
- 409 15. Pons ML, Loftus N, Vialaret J, Moreau S, Lehmann S, Hirtz C. Proteomics Challenges for
- 410 the Assessment of Synuclein Proteoforms as Clinical Biomarkers in Parkinson's Disease.
- 411 Front Aging Neurosci 2022;14:818606.
- 412 16. Hansson O, Lehmann S, Otto M, Zetterberg H, Lewczuk P. Advantages and
- 413 disadvantages of the use of the CSF Amyloid  $\beta$  (A $\beta$ ) 42/40 ratio in the diagnosis of
- 414 Alzheimer's Disease. Alzheimers Res Ther 2019;11:34.
- 415 17. McGlinchey RP, Ni X, Shadish JA, Jiang J, Lee JC. The N terminus of α-synuclein
- dictates fibril formation. Proc Natl Acad Sci USA 2021;118: e2023487118.
- 417 18. Sorrentino ZA, Giasson BI. The emerging role of α-synuclein truncation in aggregation
  418 and disease. J Biol Chem 2020;295:10224–44.
- 19. Wenning GK, Krismer F. Chapter 19 Multiple system atrophy in Handbook of Clinical
- 420 Neurology. Elsevier 2013;117:229–41.

Synuclein quantitation in plasma using LC-MRM

- 421 20. Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson's
- 422 disease. Lancet Neurol 2021;20:385–97.
- 423 21. Hughes AJ, Daniel SE, Kilford L, Lees A J. Accuracy of clinical diagnosis of idiopathic
- 424 Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg
- 425 Psychiatry 1992;55:181–4.
- 426

Synuclein quantitation in plasma using LC-MRM

#### 427 Table 1: Demographic and clinical characteristics of the plasma cohort. (UPDRS - Unified Parkinson's Disease

### 428 Rating Scale)

Disease group	PD	LBD	MSA	Control
Number of plasma samples	82	32	8	21
Mean age (years)	72.1	70.3	69.6	68.9
Sex (%M)	61.3	84.4	40	66.7
Disease duration (years)	8.44	5.48	3.73	2.57
Cognitive score (MMSE.				
MOC or MATIS) %				
Positive	30.5	50.0	9.4	9.5
Negative	17.1	37.5	87.5	52.4
N/A	52.4	12.5	3.1	38.1
Hoehn and Yahr stage				
(UPDRS V) %				
1	4.9	N/A	N/A	N/A
1.5	6.1			
2	45.1			
2.5	3.7			
3	32.9	1		
4	4.9			
N/A	2.4			

### uantitation in plasma using LC-MRM

mary of the clinical performance for each peptide, ratio and combination from α-syn and α/β-syn peptides. NA means non assigned. AUC means ε

ptide sequence	Position on $\alpha$ -syn	n α-syn Clinical performance in order : p value / sensibility / specificity /				
		under the ROC curve)				
		PD vs LBD	PD vs MSA	PD vs control		
yn EGVVAAAEK	13-21	0.344 / NA / NA / NA	0.989 / NA / NA / NA	0.028 / 0.830 / 0.670		
				0.656		
n QGVAEAAGK	34-32	0.033 / 0.490 / 0.780 /	0.989 / NA / NA NA	0.001 / 0.830 / 0.760		
		0.629		0.726		
yn EGVLYVGSK	35-43	0.001 / 0.700 / 0.690 /	0.571 / NA / NA / NA	0.0001 / 0.840 / 0.760		
		0.694		0.787		
a-syn	61-80	0.710 / NA / NA / NA	0.372 / NA / NA / NA	0.021 / 0.870 / 0.670		
GGAVVTGVTAVAQK				0.664		
'EGAGSIAAATGFVK	81-96	0.341 / NA / NA / NA	0.436 / NA / NA / NA	0.213 / NA / NA / NA		
ΞGVLYVGSK / α-syn	Peptide Ratio	0.0003 / 0.7 / 0.7 /	0.0084 / 0.80 / 0.85 /	>0.05 / NA / NA / NA		
GGAVVTGVTAVAQK		0.719	0.784			

uantitation in plasma using LC-MRM

Peptide	0.0001 / 0.7 / 0.68 /	0.0021 / 0.84 / 0.85 /	0.0003 / 0.83 / 0.58 /
combination	0.743	0.831	0.757
	Peptide combination	Peptide         0.0001 / 0.7 / 0.68 /           combination         0.743	Peptide         0.0001 / 0.7 / 0.68 /         0.0021 / 0.84 / 0.85 /           combination         0.743         0.831

Synuclein quantitation in plasma using LC-MRM

Figure list

Figure 1: Workflow of the analysis of the synucleins peptides in plasma by liquid chromatography-mass spectrometry with multiple reaction monitoring mode

Figure 2: Comparison of the PD group with the other synucleinpathies (MSA and LBD) and the control group with the model ( $\alpha$ -syn [EQVTNVGGAVVTGVTAVAQK]\*-0.011268 +  $\alpha/\beta$ -syn [EGVLYVGSK] \* 0.0096545).

Figure 3A: ROC curve monitoring the clinical performance (sensitivity and specificity) for the peptide combination when PD is compared to LBD patients.

Figure 3B: ROC curve monitoring the clinical performance (sensitivity and specificity) for the peptide combination when PD is compared to MSA.

# **Conflict of Interest**

The authors have no conflict of interest to report. Mass spectrometry experiments were carried out using the facilities of the Montpellier Proteomics Platform (PPM-PPC, BioCampus Montpellier). This article has been written in the context of the "innovation center" of Shimadzu Europa GmbH. All figures were created with the Biorender.com website.



Recombinant and labelled U-<sup>15</sup>N standards of synuclein in plasma



Dessalting with RP-W

tips AssayMap Bravo Agilent technologies.



Enzymatic digestion with tryspin/LysC



**LC-SRM analysis** Shimadzu TQ 8060.

Intensity





- ---- EGWAAAEK
- ---- EGVLYGSK/EQVTNVGGAVVTGVTA/AQK
- Model